Skip to main content
SpringerLink
Log in

Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol

  • Original Articles
  • Cross-Resistance, DNA Drug Adducts, Cross-Linking, BCNU, Galactitol
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Dianhydrogalactitol (DAG) increased the life span of both BCNU-sensitive and-resistant L1210 tumorbearing mice. However, the BCNU-resistant strain showed slightly lower sensitivity against DAG, which could be overcome by an increase in drug dose of ca. 20%. The somewhat lower sensitivity was proportional to a slightly reduced DNA cross-linking formation induced by DAG in BCNU-resistant cells. The amount of DNA cross-links was determined by measurement of the 1,6-di(guaninyl)-galactitol content of DNA. The slight reduction in cross-links is not attributable to DNA repair but rather to other factors that seem to prevent the formation of DNA-drug adducts. The absence of cross-resistance is explained by different kinds of DNA damage caused by the two alkylating agents and the presumably different defense mechanisms developed by cells against these lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmann DL, O'Connell MI, Bisel HF, Edmondson JH, Hahn RG, Frytak S (1977) Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer Treat Rep 61: 81–82

    Google Scholar 

  2. Bence J, Somfai-Relle S, Gáti É (1986) Development and some characteristics of a P388 leukemia strain resistant to 1,2:5,6-dianhydrogalactitol. Eur J Cancer Clin Oncol 22: 773–780

    Google Scholar 

  3. Csányi E, Halász M (1967) Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol (DBM)-resistant Yoshida s. c. sarcoma. Br J Cancer 21: 353–357

    Google Scholar 

  4. Eagan RT, Ames MM, Powis G, Kovach JS (1982) Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol. Cancer Treat Rep 66: 283–287

    Google Scholar 

  5. Eagan RT, Dinapoli RP, Hermann RC, Groover RV, Layton DD, Scott M (1982) Combination of carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. Cancer Treat Rep 66: 1647–1649

    Google Scholar 

  6. Frei E III, Cucchi CA, Rosowsky A, Tantravahi R, Bernal S, Ervin TJ, Ruprecht RM, Haseltine WA (1985) Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 82: 2158–2162

    Google Scholar 

  7. Gáti É (1968) Studies on cross-resistance to degranol-and dibromodulcitol-resistant Yoshida tumours. Int J Cancer 3: 260–264

    Google Scholar 

  8. Goldenberg GJ (1975) The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L5178Y lymphoblasts. Cancer Res 35: 1687–1692

    Google Scholar 

  9. Haas CD, Baker L, Thigpen T (1981) Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology group study. Cancer Treat Rep 65: 115–117

    Google Scholar 

  10. Institoris E (1981) In vivo study on alkylation sites in DNA by the bifunctional dianhydrogalactitol. Chem Biol Interact 35: 207–216

    Google Scholar 

  11. Institoris E (1982) DNA alkylation sites and cytotoxicity in Yoshida sarcoma cells treated with bifunctional galactitols. In: Petri P, Grassi GG (eds) Current chemotherapy and immunotherapy. American Society of Microbiology, Washington DC, pp 1378–1380

    Google Scholar 

  12. Institoris E, Tamás J (1980) Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine. Biochem J 185: 659–666

    Google Scholar 

  13. Institoris E, Tamás J (1983) Identification of guanine and adenine adducts in DNA alkylated by dibromodulcitol in vitro and in vivo. Chem Biol Interact 47: 133–144

    Google Scholar 

  14. Institoris E, Tamás J, Somfai-Relle S (1985) Sites and extents of alkylation in tumour cell DNA and their relation to antitumour effects of dibromodulcitol and dianhydrogalactitol. In: Eckhardt S, Kerpel-Fronius S (eds) CMEA chemotherapy symposium. Akadémiai Kiadó, Budapest, pp 353–358

    Google Scholar 

  15. Reference deleted

  16. Jeney A, Szabó J, Vályi-Nagy T (1968) Investigation on the mechanism of action of cytotoxic hexitols: I. Cross-resistance investigation on Yoshida sarcoma tumours. Neoplasma 15: 231–240

    Google Scholar 

  17. Kirby KS (1975) New method for isolation of DNA: evidence on the nature of bonds between DNA and protein. Biochem J 66: 459–499

    Google Scholar 

  18. Németh L, Institoris L, Somfai S, Gál F, Pályi I, Sugár J, Csuka O, Szentirmay Z, Kellner B (1972) Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC 132313). Cancer Chemother Rep 56(1): 539–602

    Google Scholar 

  19. Robins P, Harris AL, Goldsmith I, Lindahl T (1983) Crosslinking of DNA induced by chloroethylnitrosourea is prevented by O6-methylguanine DNA methyltransferase. Nucleic Acids Res 11: 7743–7758

    Google Scholar 

  20. Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905–922

    Google Scholar 

  21. Skipper HE, Hutchinson DJ, Schabel FM Jr, Schmidt LH, Goldin A, Brockman RW, Venditti JM, Wodenski I (1972) A quick reference chart on cross-resistance between anticancer agents. Cancer Chemother Rep 56: 493–498

    Google Scholar 

  22. Reference deleted

  23. Ujházy V, Winkler A (1965) Nitrogen mustard-resistant Yoshida sarcoma and cross-resistance studies. Neoplasma 12: 11–14

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Oncology, Ráth Gy. u. 7-9, 1122, Budapest, Hungary

    Etel Institóris, Károly Szikla & Ferenc Gál

  2. Central Research Institute for Chemistry, Hungarian Academy of Sciences, Pusztaszeri-u. 57-59, 1525, Budapest, Hungary

    László Ötvös

Authors
  1. Etel Institóris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Károly Szikla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. László Ötvös
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ferenc Gál
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Institóris, E., Szikla, K., Ötvös, L. et al. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol. Cancer Chemother. Pharmacol. 24, 311–313 (1989). https://doi.org/10.1007/BF00304764

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00304764

Keywords

Search

Navigation